DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Cardiology Homepage

FDA gives nod to Stryker’s Neuroform Atlas Stent System Treats wide neck, intracranial, and saccular aneurysms

Neusoft's NueViz Prime 128-slice CT scores FDA clearance High-speed system may improve imaging in trauma, pediatrics and cardiac cases

Updated guidelines recommend use of S-ICDs for patients with ventricular arrhythmia Call to action for physicians

Konica Minolta signs group purchasing agreement with Premier for the Exa platform The three-year deal brings special pricing to 3,900 hospitals

A look at pheno-mapping in cardiovascular imaging Transforms data from cardiac imaging into an 'imaging phenotype'

Global interventional X-ray market to be worth over $3 billion in 2021 Low-volume facilities are purchasing new systems

Despite Brexit, ESC Congress will return to London in 2021 Decision based in large part on Mayor's active lifestyle initiative

In Mexico, a call for sterilized, used pacemakers as implants in new study An alternative for those who cannot afford new pacemakers

Image-guided Harpoon device safe and effective for mitral valve heart repair: study Less invasive than conventional mitral valve surgery

Global cardiac pacemaker market to almost double by 2023 As people live longer, cardiovascular disease becomes more prominent

Spectranetics' Stellarex
drug-coated balloon

Philips to acquire cardiac device company Spectranetics for €1.9 billion

by Lauren Dubinsky , Senior Reporter
Royal Philips announced a €1.9 billion deal on Wednesday to acquire The Spectranetics Corporation, with the goal of expanding its Image-Guided Therapy Business Group.

“Today’s exciting announcement follows a series of bolt-on acquisitions to strengthen our portfolio across the health continuum,” Frans van Houten, CEO of Philips, said in the announcement.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Late last week, Philips made an agreement to acquire the EEG technology manufacturer, Electrical Geodesics Inc., for approximately €32.9 million. In 2014, the company purchased the catheter-based imaging company, Volcano Corporation, for $1.2 billion.

Spectranetics is a leader in the fields of vascular intervention and lead management, which involves the minimally-invasive removal of implanted pacemakers and ICD leads. The company is currently growing in the double digits and expects its 2017 sales to be in the range of $293 million to $306 million.

Its portfolio includes a line of laser atherectomy catheters for treating blockages in coronary and peripheral arteries and the AngioSculpt scoring balloon to mechanically push the blockage aside. It also sells the only drug-coated scoring balloon on the market, which is called AngioSculptX, as well as the Stellarex drug-coated balloon that treats common to complex lesions and prevents blockage recurrence.

The Stellarex, which is CE marked and is under review for FDA approval, is Spectranetics’ most popular product. It’s been studied in drug-coated balloon IDE trials on the most complex patient population and demonstrated excellent clinical performance.

Philips is already a major player in the image-guided therapy market, which is valued at more than €6 billion. The company believes that Spectranetics will help it further expand and strengthen its stake in the market.

“Spectranetics’ highly competitive product range, integrated with our portfolio of interventional imaging systems, devices, software and services will enable clinicians to decide, guide, treat and confirm the appropriate cardiac and peripheral vascular treatment,” said van Houten.

“We believe that [Spectranetics’] product portfolio complements the Volcano vascular imaging [including intravascular ultrasound or IVUS and fractional flow reserve or FFR] and therapeutic product portfolio,” Mike Matson, analyst at Needham, told Yahoo! Finance.

He added that given the premium Philips is paying, and the short list of other potential buyers, that another bidder is unlikely.

Once the transaction is complete, Spectranetics and its 900-plus employees will become part of Philips’ Image-Guided Therapy Business Group, also known as Philips Volcano. The group is expected to grow to about €1 billion by 2020.

Philips plans to have the deal close in the third quarter of this year.

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED